US5653962A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Aerosol formulations containing P134a and particulate medicaments
Assignee: Glaxo Group Ltd
•
Filing: 1995-05-19
•
Granted: 1997-08-05
•
Expires: 2015-05-19
Abstract
Abstract This invention relates to a pharmaceutical aerosol formulation containing a particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof end 1,1,1,2-tetrafluoroethane as propellant, which formulation is free of surfactant or has less than 0.0001 % w/w surfactant based on the weight of medicament. The formulation may contain a further particulate medicament which is salbutamol, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation is also described.
Inventors
- 👤 Rachel Ann Akehurst
- 👤 Anthony James Taylor
- 👤 David Andrew Wyatt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 20:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/137; A61K31/138; A61K31/16; A61K31/165; A61K31/167; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/4402; A61K31/445; A61K31/4458; A61K31/4523; A61K31/4535; A61K31/47; A61K31/4738; A61K31/4741; A61K31/48; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K31/522; A61K31/56; A61K31/57; A61K31/573; A61K45/00; A61K45/06; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; A61K9/008
Claims Analysis
Total Claims: 44
Claim 1
Independent Claim
71 words
A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, the particulate medicament being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
Claim 2
Dependent Claim
71 words
A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, the particulate medicament being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
Claim 3
Dependent Claim
29 words
A formulation as claimed in claim 1 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 4
Dependent Claim
21 words
A formulation as claimed in claim 1 which has a respirable fraction of 20% or more by weight of particulate medicament.
Claim 5
Dependent Claim
18 words
A formulation as claimed in claim 1 wherein the salmeterol is in the form of its xinafoate salt.
Claim 6
Dependent Claim
63 words
A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellent, the particulate medicament being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, which formulation is free of surfactant.
Claim 7
Dependent Claim
63 words
A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellent, the particulate medicament being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, which formulation is free of surfactant.
Claim 8
Dependent Claim
55 words
A pharmaceutical aerosol formulation consisting of particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
Claim 9
Dependent Claim
55 words
A pharmaceutical aerosol formulation consisting of particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
Claim 10
Dependent Claim
29 words
A formulation as claimed in claim 5 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 11
Dependent Claim
29 words
A formulation as claimed in claim 6 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 12
Dependent Claim
18 words
A formulation as claimed in claim 5 wherein the salmeterol is in the form of its xinafoate salt.
Claim 13
Dependent Claim
18 words
A formulation as claimed in claim 6 wherein the salmeterol is in the form of its xinafoate salt.
Claim 14
Dependent Claim
21 words
A formulation as claimed in claim 5 which has a respirable fraction of 20% or more by weight of particulate medicament.
Claim 15
Dependent Claim
21 words
A formulation as claimed in claim 6 which has a respirable fraction of 20% or more by weight of particulate medicament.
Claim 16
Dependent Claim
89 words
A pharmaceutical aerosol formulation consisting essentially of particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof, a particulate medicament selected from the group consisting of salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof, and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, the particulate medicaments being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
Claim 17
Dependent Claim
89 words
A pharmaceutical aerosol formulation consisting essentially of particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof, a particulate medicament selected from the group consisting of salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof, and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, the particulate medicaments being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
Claim 18
Dependent Claim
74 words
A pharmaceutical aerosol formulation consisting of particulate medicament consisting of salmeterol or a physiologically acceptable salt or solvate thereof, a particulate medicament selected from the group consisting of salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof, and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicaments being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
Claim 19
Dependent Claim
74 words
A pharmaceutical aerosol formulation consisting of particulate medicament consisting of salmeterol or a physiologically acceptable salt or solvate thereof, a particulate medicament selected from the group consisting of salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof, and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicaments being present in an amount of from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
Claim 20
Dependent Claim
29 words
A formulation as claimed in claim 13 wherein the particulate medicaments are present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 21
Dependent Claim
29 words
A formulation as claimed in claim 14 wherein the particulate medicaments are present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 22
Dependent Claim
18 words
A formulation as claimed in claim 13 wherein the salmeterol is in the form of its xinafoate salt.
Claim 23
Dependent Claim
18 words
A formulation as claimed in claim 13 wherein the salmeterol is in the form of its xinafoate salt.
Claim 24
Dependent Claim
22 words
A formulation as claimed in claim 13 which has a respirable fraction of 20% or more by weight of the particulate medicaments.
Claim 25
Dependent Claim
22 words
A formulation as claimed in claim 14 which has a respirable fraction of 20% or more by weight of the particulate medicaments.
Claim 26
Dependent Claim
13 words
A formulation as claimed in claim 13 which formulation is free of surfactant.
Claim 27
Dependent Claim
23 words
A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation of claim 1.
Claim 28
Dependent Claim
29 words
A method as claimed in claim 22 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 29
Dependent Claim
18 words
A method as claimed in claim 22 wherein the salmeterol is in the form of its xinafoate salt.
Claim 30
Dependent Claim
21 words
A method as claimed in claim 22 which has a respirable fraction of 20% or more by weight of particulate medicament.
Claim 31
Dependent Claim
23 words
A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation of claim 5.
Claim 32
Dependent Claim
18 words
A method as claimed in claim 26 wherein the salmeterol is in the form of its xinafoate salt.
Claim 33
Dependent Claim
29 words
A method as claimed in claim 26 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 34
Dependent Claim
23 words
A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation of claim 6.
Claim 35
Dependent Claim
29 words
A method as claimed in claim 29 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 36
Dependent Claim
18 words
A method as claimed in claim 29 wherein the salmeterol is in the form of its xinafoate salt.
Claim 37
Dependent Claim
21 words
A method as claimed in claim 29 which has a respirable fraction of 20% or more by weight of particulate medicament.
Claim 38
Dependent Claim
19 words
A method of treating respiratory disorders which comprises administration by inhalation of the pharmaceutical aerosol formulation of claim 13.
Claim 39
Dependent Claim
29 words
A method as claimed in claim 33 wherein the particulate medicaments are present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 40
Dependent Claim
18 words
A method as claimed in claim 33 wherein the salmeterol is in the form of its xinafoate salt.
Claim 41
Dependent Claim
22 words
A method as claimed in claim 33 which has a respirable fraction of 20% or more by weight of the particulate medicaments.
Claim 42
Dependent Claim
19 words
A method of treating respiratory disorders which comprises administration by inhalation of the pharmaceutical aerosol formulation of claim 14.
Claim 43
Dependent Claim
28 words
A method as claimed in claim 37 wherein particulate medicaments are present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
Claim 44
Dependent Claim
18 words
A method as claimed in claim 37 wherein the salmeterol is in the form of its xinafoate salt.
References Cited (Backward Citations)
US2868691A
Cited
US2885427A
Cited
US3014844A
Cited
US3219533A
Cited
US3320125A
Cited
DK134923B
Cited
US4044126A
Cited
US3809294A
Cited
US3897779A
Cited
DE2703119C2
Cited
US4405598A
Cited
US4174295A
Cited
US4347236A
Cited
SE437766B
Cited
WO1986004233A1
Cited
US4814161A
Cited
EP0372777A2
Cited
US5225183A
Cited
WO1990007333A1
Cited
WO1991004011A1
Cited
WO1991011173A1
Cited
WO1991011495A1
Cited
WO1991011496A1
Cited
US5118494A
Cited
WO1991014422A1
Cited
WO1992000107A1
Cited
US5126123A
Cited
US5230884A
Cited
WO1992006675A1
Cited
WO1992008446A1
Cited
WO1992008447A1
Cited
WO1992011190A2
Cited
US5182097A
Cited
US5190029A
Cited
EP0504112A2
Cited
WO1992022287A1
Cited
WO1992022288A1
Cited
WO1993011745A1
Cited
WO1993011743A1
Cited
WO1993011744A1
Cited
WO1993011747A1
Cited
US5202110A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-08-04 | 2001-02-03 | 2001-08-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-08-04 | 2005-02-03 | 2005-08-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-08-04 | 2009-02-03 | 2009-08-05 | $7700.00 | Window Closed / Lapsed |